Clinical Trials

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT07486687 2026-03-20

PLANET

1,000 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT00905047 2026-03-13

COLOCROSS

89 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT01918527 2026-03-10

Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer

250 enrolled

Colonic Neoplasms

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT02767661 2026-02-27

MECCA

263 enrolled

Breast Neoplasms

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

446 enrolled

Colorectal Neoplasms

NCT07113275 2026-02-12

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

435 enrolled

Rectal Neoplasms

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

550 enrolled

Rectal Neoplasms

NCT03399110 2026-01-27

XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)

1,024 enrolled

Stomach Neoplasms

NCT07340567 2026-01-14

CIRCULATEIII

2,450 enrolled

Colorectal Neoplasms

NCT04095299 2026-01-08

WW3

162 enrolled

Rectal Neoplasms

NCT02314182 2025-12-19

GRECCAR8

5 enrolled

Rectal Neoplasms

NCT07277842 2025-12-11

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

382 enrolled

Locally Advanced Low Rectal Adenocarcinoma

NCT04595565 2025-11-25

SASCIA

1,332 enrolled

Triple Negative Breast Neoplasms

NCT07248670 2025-11-25

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

252 enrolled

Nasopharyngeal Carcinoma

NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

516 enrolled

Nasopharyngeal Cancinoma (NPC)

NCT02505750 2025-09-29

OPERA

148 enrolled

Rectal Neoplasms

NCT04158362 2025-09-22

AMBRE

180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07177794 2025-09-17

EC-CRT-008

242 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

325 enrolled

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

226 enrolled

Breast Neoplasms

NCT05387603 2025-09-10

START-NET

300 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05063786 2025-09-08

ALPHABET

27 enrolled

Breast Neoplasms

NCT06207981 2025-09-02

KANALRAD

310 enrolled

Anus Neoplasms

NCT06490536 2025-08-29

The Sagittarius Trial

700 enrolled

Colonic Neoplasms

NCT02605265 2025-08-28

CinClare

356 enrolled

Locally Advanced Rectal Cancer

NCT07132008 2025-08-20

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

94 enrolled

Colonic Neoplasms

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT03828227 2025-07-18

COLAGE

49 enrolled

Colorectal Neoplasms

NCT06992882 2025-07-18

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

2,306 enrolled

HER2-positive Breast Cancer

NCT06507371 2025-06-26

mRCAT-III

170 enrolled

Rectal Neoplasms

NCT06850090 2025-06-25

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

210 enrolled

Rectal Neoplasms

NCT01354522 2025-06-15

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

204 enrolled

Breast Neoplasms

NCT07021261 2025-06-13

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

440 enrolled

Breast Neoplasms

NCT01804790 2025-06-12

Néofirinox

461 enrolled

Neoplasms, Rectal Neoplasms

NCT02934529 2025-04-16

AIO-KRK-0114

673 enrolled

Colorectal Neoplasms

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

664 enrolled

Nasopharyngeal Carcinoma

NCT02170090 2025-03-30

ACTICCA-1

789 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma

NCT02572141 2025-03-19

OPTICAL

738 enrolled

Colonic Neoplasms

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

166 enrolled

Nasopharyngeal Carcinoma

NCT01167725 2024-12-27

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Phase 3 Terminated

340 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06533384 2024-11-04

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

310 enrolled

Triple Negative Breast Neoplasms

NCT02028507 2024-09-25

PEARL

693 enrolled 40 charts

Breast Neoplasms

NCT04488159 2024-09-20

iMAGINE

Phase 3 Withdrawn

Colonic Neoplasms, Motor Activity

NCT04246684 2024-09-19

Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

702 enrolled

Rectal Neoplasms

NCT02514278 2024-08-14

GRECCAR12

218 enrolled

Rectal Neoplasms

NCT02355379 2024-07-08

ADAGE

774 enrolled